Galeterone, also known as TOK-001 and NX41765; is an orally bioavailable small-molecule androgen receptor modulator and CYP17 lyase inhibitor with potential antiandrogen activity. Galeterone exhibits three distinct mechanisms of action: 1) as an androgen receptor antagonist, 2) as a CYP17 lyase inhibitor and 3) by decreasing overall androgen receptor levels in prostate cancer tumors, all of which may result in a decrease in androgen-dependent growth signaling.
P450 (e.g. CYP17) inhibitor Related Products:
Abiraterone; Abiraterone acetate; Ketoconazole; Orteronel(racemic); Orteronel; Cobicistat; Ozagrel; Ritonavir; Posaconazole; Voriconazole; Fluconazole; Clarithromycin